Strategic cooperation between ARTES Biotechnology and PAC

ARTES and PAC join forces

Langenfeld, (PresseBox) - Artes and PAC join forces and combine their technologies and know-how.
ARTES Biotechnology specializes in recombinant protein production, process development in microbial expression systems and is a technology provider for pharmaceutical processes, while PAC (Peschek Analytic Consulting) is highly skilled in the field of protein analysis and quality control. Together with PAC, ARTES will now prospectively offer analysis of product quality control along side determination and quantification of by-products and/or process related residuals. The method analysis portfolio of PAC allows ARTES to offer method development and validation in accordance with GMP guidelines in the following analytical methods as HPLC-UV/DAD, Mass Spectrometry Ion Trap (LC-ESI/APCI MS/MS), Mass spectrometry Quadrupole (LC-ESI-MS), Gas Chromatography-Mass Spectrometry, Capillary Electrophoresis, Dynamic Light Scattering and Electron Microscopy.

Website Promotion

ARTES Biotechnology GmbH

ARTES Biotechnology GmbH – www.artes-biotechnology.com
ARTES is a Germany-based biotechnology company, specializes in recombinant protein production, process development from microbial expression systems and technology transfer. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha and vaccine development on virus like particle technology (VLP). In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld. The company focuses on contract R&D for red and white biotechnology products.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.


Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.